David Archer

Obstetrics & Gynecology / Reproductive Endocrinology

Credentials: · ·

History

A Phase 2b Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
National Institute of Child Health and Human Development · N01
Contact PI · $94.1K · Columbia University Health Sciences
2025–2026
On Demand Oral Contraception for Obese Women
National Institute of Child Health and Human Development · R43
Contact PI · $382.4K · Innovagyn, Inc.
2023–2025
Novel On Demand Female Oral Contraceptive
National Institute of Child Health and Human Development · R43
Contact PI · $300K · Innovagyn, Inc.
2021–2023
Doxycycline for Bleeding in Progestin Only Contraceptors
National Institute of Child Health and Human Development · R01
Contact PI · $1.4M · Eastern Virginia Medical School
2002–2008

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
Principal investigator · Completed · Phase 2
InnovaGyn, Inc.
2022–2025
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
Principal investigator · Completed · Phase 3
EndoCeutics Inc.
2014–2015
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Principal investigator · Completed · Phase 3
EndoCeutics Inc.
2011–2012
DHEA Against Vaginal Atrophy - 3-Month Efficacy Study
Principal investigator · Completed · Phase 3
EndoCeutics Inc.
2010–2011